1-(4-硝基苯基)-1-戊酮 | 22857-30-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-硝基苯基)-1-戊酮
• 英文名称: 1-(4-nitrophenyl)pentan-1-one
• 英文别名: 1-(4-nitro-phenyl)-pentan-1-one；1-(4-Nitro-phenyl)-pentan-1-on；4'-nitrovalerophenone；n-Butyl-(4-nitrophenyl)-keton；p-Nitro-n-valerophenon
• CAS: 22857-30-3
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: LQCRSKSCUSXMJH-UHFFFAOYSA-N

物化性质

• 熔点：
  34-35 °C
• 沸点：
  318.6±15.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  1-(4-硝基苯基)-1-戊酮 在 ammonium acetate 、 sulfur 、 溶剂黄146 、 二乙胺 作用下， 以 乙醇 、 苯 为溶剂， 反应 19.5h， 生成 2-Amino-4-(4-nitro-phenyl)-5-propyl-thiophene-3-carbonitrile
  参考文献：
  名称：

  Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N '-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. A kinase insert domain-containing receptor (KDR) homology model suggests that these compounds bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the adenosine 5 '-triphosphate (ATP) binding site. A number of compounds have been identified as displaying excellent in vivo potency. In particular, compounds 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg-day, per os (po)).

  DOI：

  10.1021/jm050458h
• 作为产物：
  描述：

  N-(4-戊酰苯基)-乙酰胺 在 copper(II) sulfate 、 sodium nitrite 作用下， 生成 1-(4-硝基苯基)-1-戊酮
  参考文献：
  名称：

  Sugimoto et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 1161

  摘要：

  DOI：

文献信息

• Tetraorganogallate complexes in organic chemistry: A novel, efficient and versatile preparation of ketones from acyl chlorides
  作者：Ying Han、Lei Fang、Tao Wen-Tian、Huang Yao-Zeng

  DOI：10.1016/0040-4039(95)00057-j

  日期：1995.2

  Tetraorganogallium ate complexes, prepared in situ by addition of an organolithium reagent to a triorganogallium, reacted smoothly with acyl chlorides to yield ketones in high yields and mixed ate complexes display high chemoselectivity in the transfer of one of their ligands.

  通过将有机锂试剂添加到三有机镓中原位制备的四有机镓盐配合物与酰氯平滑反应，以高收率产生酮，并且混合盐配合物在其配体之一的转移中显示出高化学选择性。
• Regioselective Nitration of Deactivated Mono-Substituted Benzenes Using Acyl Nitrates Over Reusable Acidic Zeolite Catalysts
  作者：Keith Smith、Mansour D. Ajarim、Gamal A. El-Hiti

  DOI：10.1007/s10562-009-0258-7

  日期：2010.2

  Nitration of benzonitrile was investigated using a nitric acid/acid anhydride/zeolite catalyst system under different reaction conditions. Trifluoroacetic and chloroacetic anhydrides were found to be the most active among the anhydrides tried. Also, zeolites Hβ and Fe3+β (Si/Al = 12.5) were found to be the most active catalysts. For example, nitration of benzonitrile with trifluoroacetyl nitrate under

  使用硝酸/酸酐/沸石催化剂体系在不同反应条件下研究了苄腈的硝化。发现三氟乙酸和氯乙酸酐在所尝试的酸酐中活性最高。此外，发现沸石 Hβ 和 Fe3+β (Si/Al = 12.5) 是最活跃的催化剂。例如，在二氯甲烷中回流条件下用三氟乙酰硝酸酯硝化苯甲腈，得到定量产率的 3- 和 4-硝基苯甲腈，其中对位异构体占 24-28%。当在类似反应条件下使用钝化的 Hβ 时，对位异构体的产率提高到 33%。这很容易成为有记录以来对苯甲腈最具对位选择性的硝化反应。而且，在尝试的条件下没有形成邻位异构体。沸石很容易回收，通过加热再生并重复使用最多六次，其结果与使用新鲜催化剂样品获得的结果相似。该硝化系统成功地应用于一系列失活的单取代苯，以显着高于相应的传统硝化反应的比例得到对位异构体。
• Anti-depressive compounds
  申请人：U.S. Philips Corporation

  公开号：US04192893A1

  公开（公告）日：1980-03-11

  The novel compounds of formula I and salts thereof have a very powerful anti-depressive activity which for a considerable part, and in some substances even entirely, is based on serotonine potentiation. Moncamino oxidase inhibition does not contribute to the anti-depressive effect. The substances are little toxic and substantially free from side effects. The compounds can be synthesized and processed to compositions according to known methods.

  公式I和其盐的新化合物具有非常强大的抗抑郁活性，其中相当大一部分，甚至在某些物质中完全基于血清素增强作用。单胺氧化酶抑制对抗抑郁效果没有贡献。这些物质毒性小，基本没有副作用。这些化合物可以按照已知方法合成和加工成组成物。
• Alicyclic diamines, alicyclic diisocyanates and polyisocyanato-isocyanurates and method for the preparation thereof
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0394058A1

  公开（公告）日：1990-10-24

  Herein disclosed are an α-(aminocydonexyl)alkylamine represented by the following general formula (II): wherein R represents hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms, provided that the amino group bonded to the cyclohexyl group may be in either of the 2-, 3- and 4-positions and a method for preparing it; an a-(isocyanatocyclohexyl)alkylisocyanate of Formula (II) wherein the amino groups are replaced with isocyanato groups and a method for preparing it; polyisocyanato-isocyanurate represented by the following general formula (IV): wherein Ri, R2 and R3 may be the same or different and each represents a group represented by the following general formula: wherein R represents hydrogen atom or an alkyl group having 1 to 5 carbon atoms and n is an integer ranging from 1 to 5 and a method for preparing it; and a resin obtained by polymerizing an organic polyisocyanate containing not lower than 10% by weight of the polyisocyanato-isocyanurate represented by Formula (IV) and a compound having at least two active hydrogen atoms as well as a resin composition for coating materials which comprises the resin.

  本发明公开了由以下通式(II)代表的α-(氨基环己基)烷基胺： 其中 R 代表氢原子或具有 1 至 5 个碳原子的低级烷基，但与环己基键合的氨基可位于 2、3 和 4 位中的任一位置；式（II）的 a-(异氰基环己基)烷基异氰酸酯（其中氨基被异氰酸基取代）及其制备方法；由以下通式（IV）表示的聚异氰酸酯： 其中 Ri、R2 和 R3 可以相同或不同，且各自代表下式通式所代表的基团： 其中 R 代表氢原子或具有 1 至 5 个碳原子的烷基，n 为 1 至 5 的整数，以及制备方法；通过聚合有机多异氰酸酯获得的树脂，该有机多异氰酸酯含有不低于 10%（按重量计）的由式(IV)代表的多异氰酸酯和至少具有两个活泼氢原子的化合物，以及包含该树脂的用于涂层材料的树脂组合物。
• AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3533796A1

  公开（公告）日：2019-09-04

  Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.

  本发明提供了一种由以下结构式表示的氨基吡唑嘧啶化合物，用作神经营养因子酪氨酸激酶受体抑制剂。该化合物可抑制 Trk 激酶的活性，并可治疗哺乳动物体内由 Trk 酪氨酸激酶受体介导的疾病。